CGRP Inhibitors for Migraine Prevention
For adults with episodic or chronic migraine who have failed two oral preventive agents, initiate a CGRP monoclonal antibody (eptinezumab, erenumab, fremanezumab, or galcanezumab) or the gepant atogepant as these are specifically indicated for treatment-refractory patients and demonstrate superior efficacy and tolerability compared to traditional oral preventives. 1
Recommended CGRP Pathway Inhibitors
First-Line CGRP Options After Oral Preventive Failure
The 2025 American College of Physicians guideline specifically addresses this clinical scenario, recommending CGRP-targeted therapies when initial oral preventives are not tolerated or provide inadequate response 1. You have two categories to choose from:
CGRP Monoclonal Antibodies:
- Eptinezumab (IV infusion)
- Erenumab (subcutaneous injection, targets CGRP receptor)
- Fremanezumab (subcutaneous injection, targets CGRP ligand)
- Galcanezumab (subcutaneous injection, targets CGRP ligand)
CGRP Receptor Antagonists (Gepants):
- Atogepant (oral, daily dosing)
- Rimegepant (oral, can be used for prevention or acute treatment) 1
Which Specific Agent to Choose
Based on network meta-analysis of treatment-refractory patients, galcanezumab 240 mg ranked first in reducing monthly migraine days (MD -4.40) and achieving ≥50% response rates (RR: 4.18), followed closely by monthly fremanezumab and eptinezumab 300 mg 2. Importantly, CGRP ligand-targeting antibodies (galcanezumab, fremanezumab, eptinezumab) demonstrated superiority over the CGRP receptor antibody erenumab in reducing monthly migraine days by an additional 1.55 days 2.
Dosing Regimens
Galcanezumab:
- 240 mg loading dose (two 120 mg injections), then 120 mg monthly subcutaneously
Fremanezumab:
- Monthly: 225 mg subcutaneously every month
- Quarterly: 675 mg subcutaneously every 3 months
Eptinezumab:
- 100 mg or 300 mg IV infusion every 3 months (300 mg dose showed superior efficacy) 2
Erenumab:
- 70 mg or 140 mg subcutaneously monthly
Atogepant:
- 10 mg, 30 mg, or 60 mg orally once daily
- Reduces monthly migraine days by 0.7-2.4 days 3
Monitoring Considerations
Initial Assessment Requirements
- Document baseline monthly migraine days (MMDs) or monthly headache days (MHDs)
- Screen for cardiovascular disease—CGRP inhibitors are contraindicated in patients with cardiovascular pathology as they inhibit vasodilation 4
- Confirm prior failure of at least 2 oral preventive medications
- Verify ≥8 migraine days per month for optimal candidacy 4
Follow-Up Evaluation
Conduct a 3-month evaluation period after initiation 5. This is critical because:
- Response rates plateau around 3 months
- 50-60% of patients achieve ≥50% reduction in attack frequency 4
- If inadequate response at 3 months, consider switching to a different CGRP inhibitor or combination therapy 5
Long-Term Monitoring
- Adverse events are typically mild (injection site reactions most common for subcutaneous formulations) 6
- Discontinuation rates are very low compared to oral preventives 4
- Long-term safety data over 10 years supports continued use 6
- No routine laboratory monitoring required
- Reassess cardiovascular status periodically given the theoretical vasodilation inhibition risk
Key Clinical Advantages in Treatment-Refractory Patients
These agents demonstrate effectiveness even in highly refractory populations:
- Effective after multiple oral preventive failures 7, 2
- Effective in chronic migraine with medication overuse 4, 8
- Superior tolerability profile compared to traditional oral preventives 1, 4
- Mechanism-based therapy specifically developed for migraine pathophysiology 6
Critical Pitfalls to Avoid
Cardiovascular contraindication: Do not use in patients with established cardiovascular disease due to inhibition of CGRP-mediated vasodilation 4. This is an absolute consideration given CGRP's role in protective vasodilation.
Premature discontinuation: Evaluate for full 3 months before declaring treatment failure, as some patients are slower responders 5.
Wrong patient selection: These agents work best in patients with ≥8 migraine days per month who have documented failure of oral preventives 4. Using them outside this context may not be cost-effective or meet insurance criteria.
Switching within class: If one CGRP antibody fails, switching to another (particularly from receptor antagonist to ligand-targeting antibody) may still provide benefit given the differential efficacy noted in network meta-analyses 2.